ジャーナル: Cell / 年: 2024 タイトル: Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. 著者: Wilton B Williams / S Munir Alam / Gilad Ofek / Nathaniel Erdmann / David C Montefiori / Michael S Seaman / Kshitij Wagh / Bette Korber / Robert J Edwards / Katayoun Mansouri / Amanda Eaton / ...著者: Wilton B Williams / S Munir Alam / Gilad Ofek / Nathaniel Erdmann / David C Montefiori / Michael S Seaman / Kshitij Wagh / Bette Korber / Robert J Edwards / Katayoun Mansouri / Amanda Eaton / Derek W Cain / Mitchell Martin / JongIn Hwang / Aria Arus-Altuz / Xiaozhi Lu / Fangping Cai / Nolan Jamieson / Robert Parks / Maggie Barr / Andrew Foulger / Kara Anasti / Parth Patel / Salam Sammour / Ruth J Parsons / Xiao Huang / Jared Lindenberger / Susan Fetics / Katarzyna Janowska / Aurelie Niyongabo / Benjamin M Janus / Anagh Astavans / Christopher B Fox / Ipsita Mohanty / Tyler Evangelous / Yue Chen / Madison Berry / Helene Kirshner / Elizabeth Van Itallie / Kevin O Saunders / Kevin Wiehe / Kristen W Cohen / M Juliana McElrath / Lawrence Corey / Priyamvada Acharya / Stephen R Walsh / Lindsey R Baden / Barton F Haynes / 要旨: A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to ...A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541). Here, we report MPER peptide-liposome induction of polyclonal HIV-1 B cell lineages of mature bnAbs and their precursors, the most potent of which neutralized 15% of global tier 2 HIV-1 strains and 35% of clade B strains with lineage initiation after the second immunization. Neutralization was enhanced by vaccine selection of improbable mutations that increased antibody binding to gp41 and lipids. This study demonstrates proof of concept for rapid vaccine induction of human B cell lineages with heterologous neutralizing activity and selection of antibody improbable mutations and outlines a path for successful HIV-1 vaccine development.